Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

MacroGenics, Takeda partner to develop four additional dart therapeutics By PBR Staff Writer
US-based biopharmaceutical firm MacroGenics and Japan-based Takeda Pharmaceutical have entered into a collaboration agreement to develop and commercialize up to four product candidates.
Contract Research & Services > Contract Services > News
Ligand earns milestone payment triggered by EU approval of Merck’s captisol-enabled NOXAFIL Ligand Pharmaceuticals Incorporated (LGND) has announced that Merck, known as MSD outside the United States and Canada, has received approval for NOXAFIL (posaconazole) 300 mg Concentrate for Solution for Infusion from the European Medicines Agency (EMA).
Contract Research & Services > Contract Services > News PharmaEngine, Merrimack amend license deal for nanoliposomal irinotecan injection By PBR Staff Writer
PharmaEngine has signed an amendment to its license agreement of MM-398 (aka PEP02, nanoliposomal irinotecan injection, nal-IRI) with Merrimack Pharmaceuticals (MACK).
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Sumitomo Dainippon, SanBio partner over SB623 cell therapy for chronic stroke
By PBR Staff Writer
Sumitomo Dainippon Pharma has entered into a joint development and license agreement with SanBio for exclusive marketing rights in the US and Canada for SB623, a cell therapy to treat patients with chronic stroke.
Contract Research & Services > Contract Services > News
EPIRUS, Livzon Mabpharm enter deal for five biosimilar products in China
By PBR Staff Writer
US-based EPIRUS Biopharmaceuticals has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm (Livzon), a Chinese biotechnology firm focused on the development, manufacture, and sale of antibody-based drugs.
Contract Research & Services > Contract Services > News
Baxter, Merrimack collaborate on new cancer compound MM-398
By PBR Staff Writer
Baxter International and Merrimack Pharmaceuticals have entered into a license and collaboration agreement worth nearly $970m, to develop and commercialize MM-398 (nanoliposomal irinotecan injection), also called as nal-IRI.
Contract Research & Services > Contract Services > News
Fujifilm Diosynth Biotechnologies - Biopharmaceutical Process Development and Manufacturing Services
We are one of the world’s leading suppliers of contract process development and manufacturing services for the biopharmaceutical industry. Created in April 2011, Fujifilm Diosynth Biotechnologies has more than 900 employees, operating from two sites in Billingham, UK, and the Research Triangle Park in North Carolina, US.
Contract Research & Services > Contract Services > Suppliers
Atara Biotherapeutics enters into immunotherapy alliance with MSK
By PBR Staff Writer
US-based Atara Biotherapeutics has entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) to develop and commercialize allogeneic T-cell therapies to treat certain cancers and persistent viral infections.
Contract Research & Services > Contract Services > News
Access Pharma announces exclusive global plasma therapeutics license, new management and new corporate name
Access Pharmaceuticals has signed an exclusive, global license agreement with Plasma Technologies (PlasmaTech) for the development and commercialization of its proprietary plasma fractionation process.
Contract Research & Services > Contract Services > News
Spectrum out-licenses rights for China to CASI Pharmaceuticals for three of its drugs
Spectrum Pharmaceuticals (SPPI) and CASI Pharmaceuticals have signed license agreements whereby CASI has been granted exclusive rights to two of Spectrum Pharmaceuticals’ commercial oncology drugs, Zevalin (ibritumomab tiuxetan) Injection for intravenous use and Marqibo (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, and a Phase 3 drug candidate, Captisol-Enabled Melphalan (CE melphalan), for development and commercialization in China, including Taiwan, Hong Kong and Macau.
Contract Research & Services > Contract Services > News
Merck Serono, Sutro Biopharma ink deal for new antibody drug conjugates
By PBR Staff Writer
Merck Serono and Sutro Biopharma have entered into collaboration and license agreement to develop antibody drug conjugates (ADCs).
Contract Research & Services > Contract Services > News
3R PHARMA CONSULTING - Reducing Regulatory Risk
3R PHARMA CONSULTING provides cost-effective, timely solutions to registration filings and challenges in pharmaceutical development strategies across Europe, the US and the rest of world.
Contract Research & Services > Contract Services > Suppliers
Manuel Zahn to Attend GMP-BERATER Tage 2014
Manuel Zahn, founder and managing director of 3R Pharma Consulting will attend the GMP-BERATER Tage 2014. The meeting will see a small group of GMP experts meet and discuss new GMP regulations and will share their experiences at Schloss Reinach, near Freiburg, Germany, 8-9 October 2014.
Contract Research & Services > Contract Services > Press Releases
View all Contract Services news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250